MARKET

VYNE

VYNE

Vyne Therapeutics Inc
NASDAQ
0.5975
+0.0095
+1.62%
After Hours: 0.5975 0 0.00% 16:10 03/31 EDT
OPEN
0.5800
PREV CLOSE
0.5880
HIGH
0.6050
LOW
0.5800
VOLUME
148.80K
TURNOVER
--
52 WEEK HIGH
1.993
52 WEEK LOW
0.2805
MARKET CAP
19.91M
P/E (TTM)
-0.9650
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VYNE last week (0323-0327)?
Weekly Report · 1d ago
Faron Pharmaceuticals appoints Heikki Jouttijärvi as CTO; late-stage development activities strengthen
Reuters · 5d ago
Weekly Report: what happened at VYNE last week (0316-0320)?
Weekly Report · 03/23 09:00
Weekly Report: what happened at VYNE last week (0309-0313)?
Weekly Report · 03/16 09:00
VYNE Therapeutics Granted Nasdaq Extension to Regain Compliance
TipRanks · 03/12 01:04
Nasdaq Grants Vyne Therapeutics Extension to Regain $1 Minimum Bid Price Compliance
Reuters · 03/11 20:58
Weekly Report: what happened at VYNE last week (0302-0306)?
Weekly Report · 03/09 09:00
Weekly Report: what happened at VYNE last week (0223-0227)?
Weekly Report · 03/02 09:00
More
About VYNE
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Webull offers Vyne Therapeutics Inc stock information, including NASDAQ: VYNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYNE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VYNE stock methods without spending real money on the virtual paper trading platform.